Kiniksa Pharmaceuticals lifts revenue outlook, shares near record high

Kiniksa Pharmaceuticals combines a higher revenue outlook with a share price close to its 52-week peak. Investors are also tracking the next earnings date and the Nasdaq listing.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 20:58.

Kiniksa Pharmaceuticals (US49704K1025) sits on the Nasdaq after a first-quarter beat and a higher 2026 outlook that Reuters said helped push the shares toward a fresh high. The latest market data shows KNSA around 57 to 60 dollars in US trading, with market commentary still anchored in that earnings reset.Reuters market commentary

What the quarter showed

Investing.com reported that Kiniksa posted first-quarter 2026 earnings of 0.27 dollars a share on revenue of 214.3 million dollars, both above expectations. The same report said the stock touched 59.89 dollars, a new all-time high, after the numbers were published.Investing.com on the all-time high

TradingKey lists KNSA at 57.09 dollars as of June 22, 16:00 ET, with a market cap of 4.36 billion dollars and a price momentum score of 9.67. That puts the Nasdaq stock in a narrow band beneath the 59.89-dollar peak, while keeping the current valuation discussion tied to live US trading.TradingKey technical page

Analysts keep watching

MarketBeat shows an active earnings calendar for Kiniksa Pharmaceuticals International, with an earnings page that tracks estimates and call transcripts for the Nasdaq listing. The company page also lists the shares at 59.60 dollars in afternoon US trade, reinforcing the current analyst-and-calendar focus.MarketBeat earnings page

For a biotech stock, that combination matters because revenue growth and earnings visibility often move together. TradingKey also said Kiniksa’s latest quarterly revenue reached 214.27 million dollars, up 55.51 percent year over year, which keeps the operating backdrop firmly in view.

The business behind the stock

Kiniksa Pharmaceuticals is built around Arcalyst, a treatment for recurrent pericarditis, and around other immune-mediated disease programs. That product mix keeps the company tied to specialty pharma, not broad-based consumer health.

Nasdaq price check

The Kiniksa Pharmaceuticals shares (US49704K1025) trade on Nasdaq at 57.09 dollars as of 2026-06-22, 16:00 ET.

Key data on Kiniksa Pharmaceuticals shares

• Company: Kiniksa Pharmaceuticals International, plc
• ISIN: US49704K1025
• Ticker: KNSA
• Trading venue: Nasdaq
• Price (as of 2026-06-22, 16:00 ET): 57.09 USD
• Market cap: 4.36 billion USD (as of 2026-06-22)
• Sector / industry: Pharmaceuticals
• Next earnings date: 2026-07-29

This article is for information only and does not constitute investment advice.